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breast cancer). To test for evidence of gene–environment interac-
tions, we compared genotypic relative risks for breast cancer
across categories of the environmental risk factors.
Methods: We tested gene–environment interactions in 7610
women who developed breast cancer and 10,196 controls without
the disease in a large UK prospective study, studying the effects of
12 polymorphisms (FGFR2-rs2981582, TNRC9-rs3803662, 2q35-
rs13387042, MAP3K1-rs889312, 8q24-rs13281615, 2p-rs4666451,
5p12-rs981782, CASP8-rs1045485, LSP1-rs3817198, 5q-rs30099,
TGFB1-rs1982073, and ATM-rs1800054) in relation to prospectively
collected information about 10 established environmental risk
factors (age at menarche, parity, age at first birth, breastfeeding,
menopausal status, age at menopause, use of hormone replace-
ment therapy, body-mass index, height, and alcohol consump-
tion).
Results: We will present findings from this systematic investi-
gation of gene–environment interactions in relation to breast can-
cer risk in the Million Women Study. Results from a meta-analysis
of these and published data will also be shown when possible.
doi:10.1016/j.ejcsup.2010.06.045
O-45 CHILDHOOD ADIPOSITY AND BREAST CANCER INCIDENCE
IN WOMEN IN MIDDLE AGE
Benjamin J. Cairns, TienYu Owen Yang, Gillian K. Reeves, Valerie
Beral, on behalf of the Million Women Study Collaborators. Cancer
Epidemiology Unit, University of Oxford, Oxford, UK
Among 397,339 postmenopausal women, breast cancer inci-
dence increases with increasing body mass index (BMI), while
adiposity in childhood has been found to lower risk. Few epidemi-
ological studies have been able to investigate joint effects of both
childhood and adult adiposity.
In a large, prospective study of postmenopausal middle-aged
women, adjusted relative risks (RR), according to BMI in middle
age and relative adiposity at age 10, were estimated by Cox regres-
sion. (Analyses were confined to non-users of hormone replace-
ment therapy, which can mask the effects of BMI on breast
cancer risk.)
Among 397,339 women, therewere 6189 incident breast cancers
over 5.2 years mean follow-up (average age at diagnosis: 63 years).
As expected, women with a high BMI in middle age had a greater
breast cancer risk (P < 0.001). In contrast, women who were plum-
per than average at age 10 had a lower risk of breast cancer than
women who were about average (P < 0.001). A similar apparently
protective effect of childhood adiposity was observed at each level
of women’s BMI in middle age (P = 0.08, NS, for interaction). These
relationships were not altered by height (P = 0.9), age at menarche
(P = 0.8), or other reproductive and hormonal risk factors (P > 0.1).
Despite the increase in risk of breast cancer with increasing
BMI among postmenopausal women, greater childhood adiposity
lowers risk in the same women. The reason for the persistent and
apparently protective effect of childhood adiposity is unclear.
doi:10.1016/j.ejcsup.2010.06.046
O-46 MACROPHAGE INFILTRATION IS ASSOCIATED WITH POOR
OUTCOME IN BREAST CANCER PATIENTS AND A REDUCED
TREATMENT RESPONSE TO LETROZOLE AND ZOLEDRONATE
A. Lee, R. Lamb, H. Gregson, A. Cramer, J. Morris, L. Renshaw, M.
Winter, R.E. Coleman, J.M.J. Dixon, G. Landberg, N.J.
Bundred. Breakthrough Breast Centre, Manchester, UK
Background: Macrophage infiltration augments tumour recur-
rence whilst Zoledronic acid suppresses macrophage pro-
tumourigenicity. In the ZO-FAST and ABCSG 12 trials, oestrogen
receptor (ER) positive breast cancer patients received Zoledro-
nate in combination with an aromatase inhibitor, Letrozole,
demonstrating an increased disease-free survival. We aimed
to investigate macrophage infiltration and patient prognosis
and the early biological effects of adjunctive Zoledronate on
patient and macrophage response to treatment in breast
cancer.
Methods: Tissue microarrays from 179 breast cancer ‘FasA
Cohort’ patients were immunohistochemically stained with
CD68, a universal macrophage marker. A randomised pre-opera-
tive trial allocated ER-positive breast cancer patients (n = 110) to
14 days pre-operative treatment of Letrozole, Letrozole and
Zoledronate, or placebo. Pre- and post-treatment specimens were
collected and immunohistochemically stained for CD68 and the
proliferation marker, Ki67.
Results: The FasA cohort found links between macrophage fre-
quency and tumour grade (P < 0.01), size (P < 0.05), recurrence
(P < 0.05) and lymph node status (P < 0.05). Ki67 reductions of 52%
(P < 0.001) were seen in the aromatase inhibitor group, with no
additional benefit following Zoledronate treatment. Macrophage
infiltrate (Mean = 37; Range = 3–117) was positively associated with
pre and post Ki67 levels (P < 0.05, P < 0.01). Additionally, low post-
treatment macrophage infiltrate (Mean = 29; Range = 3–66) was
associated with a greater reduction in Ki67 following aromatase
inhibition (P < 0.05).
Conclusion: Macrophage infiltrate correlates with poor outcome
in breast cancer. Aromatase inhibition but not Zoledronate low-
ered proliferation and macrophage infiltration in ER-positive
breast cancer. For the first time we have shown novel treatment
effects on the tumour stromal compartment.
doi:10.1016/j.ejcsup.2010.06.047
O-47 THE BASO II TRIAL AT MEDIAN 15 YEARS OF FOLLOW-UP
R.W. Blamey, A. Oates, data manager, on behalf of the
Contributors to BASO II. Nottingham City Hospital, UK
BASO II tested whether adjuvant radiotherapy or endocrine
therapy were required following Wide Local Excision: Grade I/
node negative/62 cm diameter.
The mean endpoint was Local Recurrence (in breast) (LR).
Entry was to 4-way randomisation: RT only, Tamoxifen (TAM)
only, neither, both.
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Results:
n % 10 Year LR free
RT + TAM 98 100 ± 0
RT only 110 93 ± 3
TAM only 107 93 ± 3
Neither 96 82 ± 4
Entry was also allowed to 2-way randomisation for units which
had opted to give RT or TAM to all their cases. Analysis by ran-
domisation then allowed RT versus no RT with both arms includ-
ing some cases receiving TAM by elective choice of Unit (or) TAM
versus no TAM, both including some cases receiving elective RT.
Results:





RT 571 97 ± 1 93 ± 1 20.5 <0.000
No RT 568 88 ± 2 86 ± 2
TAM 213 96 ± 2 92 ± 4 12.3 <0.000
No TAM 217 87 ± 3 83 ± 3
Analysis by treatment received confirms that results from ran-
domisation (intention to treat).
Survival overall (all cases) is 91 ± 1% at 10 years.
Conclusion:
1. Omission of any adjuvant therapy led to a recurrence rate of
1.8% per annum. This was reduced by the use of either TAM
only or RT only.
2. Use of both TAM and RT produced no LR’s.
doi:10.1016/j.ejcsup.2010.06.048
O-48 THE POST-OPERATIVE RADIOTHERAPY IN MINIMUM-RISK
ELDERLY (PRIME) RANDOMISED TRIAL OF ADJUVANT RADIO-
THERAPY AFTER BREAST CONSERVING SURGERY: IMPACT ON
QUALITY OF LIFE AND COST-EFFECTIVENESS AT 5 YEARS
I.H. Kunkler a, L.J. Williams b, R.J. Prescott b, C.C. King b, W. Jack a,
J.M. Dixon a, M. van der Pol c, T.T. Goh c, R. Lindley d, J.
Cairns e. aEdinburgh Cancer Centre, Western General Hospital,
Edinburgh, UK. bCentre for Population Health Sciences, University of
Edinburgh, UK. cHealth Economics Research Unit, University of
Aberdeen, UK. dWestmead Hospital, University of Sydney, Aus-
tralia. e London School of Hygiene and Tropical Medicine, London, UK
Objectives: To assess whether in older women with ‘low risk’
axillary node negative breast cancer (T0–2, N0, M0) treated by
breast conserving surgery and adjuvant endocrine therapy the
omission of post-operative radiotherapy affects quality of life
and is cost-effective.
Design: Randomised controlled multicentre trial.
Participants: Patients (255) with follow up to 5 years from the
end of recruitment.
Interventions: Whole breast radiotherapy (40–50 Gy) or no
breast radiotherapy.
Main outcome measures: Quality of life, anxiety and depression,
cost effectiveness.
Results: No difference in overall quality of life or anxiety and
depression was found. However, in the subscales of the EORTC
QLQ C30 and BR23 questionnaires, there were significantly higher
levels of insomnia within the non-irradiated group. By contrast,
the irradiated patients reported higher levels of breast symptoms,
and social function was slower to recover. The mean Quality
Adjusted Life Years were similar in the two arms with marginally
higher levels in the radiotherapy arm. The additional cost of pro-
viding radiotherapy was £2128 per patient. Local recurrence rates
at 5 years were 6% (95% CI 0–12%) in the non-irradiated group and
0% in the irradiated group.
Conclusion: Breast radiotherapy is tolerated well by most older
breast cancer patients without impairing their overall health
related quality of life (HRQOL). Concerns about HRQOL should
not be a primary consideration when deciding whether or not
to recommend postoperative radiotherapy after breast conserving
surgery and adjuvant endocrine therapy. The ‘no radiotherapy
option’ is cost effective in the short term.
doi:10.1016/j.ejcsup.2010.06.049
O-49 THE INFLUENCE OF PATIENT-RELATED AND SURGICAL
FACTORS ON OVERALL COSMESIS AND LATE TOXICITY AFTER
ADJUVANT BREAST RADIOTHERAPY: RESULTS FROM THE CAM-
BRIDGE INTENSITY MODULATED RADIOTHERAPY (IMRT) TRIAL
Gillian C. Barnett a, Gordon C. Wishart b, Jennifer C. Wilkinson c,
Anne M. Moody c, Charles B. Wilson c, Nicola Twyman c, Neil G.
Burnet a, Charlotte E. Coles c. aUniversity of Cambridge, Department
of Oncology, Cambridge, UK. bCambridge Breast Unit, Cambridge,
UK. cOncology Centre, Addenbrooke’s Hospital, Cambridge, UK
Background: The Cambridge Breast IMRT Trial demonstrated
that improving dose distribution using IMRT leads to significant
reduction in telangiectasia at comparatively early follow-up.
The secondary aim was to elucidate the influence of patient-
related and surgical factors on late toxicity and cosmesis.
Method: The influence of such factors on late toxicity assessed
using photographic, clinical and patient-reported endpoints at 2
years following radiotherapy was analysed in 1014 patients.
Results: Patients with a moderate or poor baseline surgical cos-
mesis had an increased risk of moderate or poor overall cosmesis
(odds ratio (OR) = 38.19; 95% CI 21.9–66.7; p < 0.0005), and of devel-
oping any clinically assessed breast shrinkage (OR = 4.96; 95% CI
3.67–6.71, p < 0.0005) and induration (OR = 2.78; 95% CI 1.92–4.01,
p < 0.0005) at 2 years. Increased breast volume was significantly
associated with the development of several late toxicity end-
points (p < 0.0005). Current smokers had an increased risk of
developing pigmentation (OR = 2.09, 95% CI 1.23–3.54; p = 0.006).
Post-operative infection requiring antibiotics was associated with
increased risk of telangiectasia (OR = 3.39, 95% CI 1.94–5.91;
p < 0.0005) and breast oversensitivity (OR = 1.78, 95% CI 1.27–
2.49; p = 0.001).
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